Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Marinus Pharmaceuticals Inc
MRNS
Healthcare
Marinus Pharmaceuticals, Inc. is a commercial-stage pharmaceutical company. The Company is engaged in the development of innovative therapeutics for the treatment of seizure disorders, including rare genetic epilepsies and status epilepticus, which includes the use of ZTALMY (ganaxolone). Its U.S. Food and Drug Administration (FDA) approved the Company’s new drug application for the use of...
ZTALMY oral suspension CV for the treatment of seizures associated with Cyclin-dependent Kinase-like 5 (CDKL5) Deficiency Disorder (CDD) in patients two years of age and older. The Company is also developing ganaxolone for the treatment of other rare genetic epilepsies, including Tuberous Sclerosis Complex (TSC) and for the treatment of Refractory Status Epilepticus (RSE). It is developing ganaxolone in formulations for two different routes of administration: intravenous (IV) and oral to maximize therapeutic reach for adult and pediatric patients in acute and chronic care settings.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:MRNS)
New Post
View:
Posts & Comments
Threaded Posts
(268)
•••
whytestocks
X
Post by
whytestocks
on Oct 24, 2024 5:15pm
Market Perform Recommendation Issued On MRNS By JMP Securiti
Breaking News: $MRNS Market Perform Recommendation Issued On MRNS By JMP Securities2024-10-24 14:15:03 ET JMP Securities analyst issues MARKET PERFORM recommendation for MRNS on October 24, 2024 12
...more
(268)
•••
whytestocks
X
Post by
whytestocks
on Jul 29, 2024 9:17pm
DEADLINE NEXT WEEK: Berger Montague Advises Marinus Pharmace
NEWS: $MRNS DEADLINE NEXT WEEK: Berger Montague Advises Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) Investors to Contact the Firm Before August 5, 2024PHILADELPHIA, July 29, 2024 (GLOBE NEWSWIRE
...more
Access North American AND Australian listed and Pre-IPO opportunities – here!
posted Dec 02, 2024 9:00am by
Stockhouse Publishing Ltd.
-
|
For the first time on Stockhouse, Canadian investors can access ASX-listed opportunities through our partnership with HotCopper in Australia, opening doors to high-potential investments at the click of a button. Learn more here… ...read more
(268)
•••
whytestocks
X
Post by
whytestocks
on Jun 12, 2024 7:15pm
Marinus Pharmaceuticals (MRNS) Securities Fraud: Contact Ber
NEWS: $MRNS Marinus Pharmaceuticals (MRNS) Securities Fraud: Contact Berger Montague To Discuss Your RightsPhiladelphia, Pennsylvania--(Newsfile Corp. - June 12, 2024) - Attention Marinus
...more
(268)
•••
whytestocks
X
Post by
whytestocks
on Jun 12, 2024 7:00pm
MRNS Investors Have Opportunity to Lead Marinus Pharmaceutic
Just In: $MRNS MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm | BenzingaLOS ANGELES, June 12, 2024 (GLOBE NEWSWIRE) -- The
...more
(268)
•••
whytestocks
X
Post by
whytestocks
on Apr 17, 2024 4:00pm
Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts
JUST IN: $MRNS Visa To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday | BenzingaTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst
...more
(268)
•••
whytestocks
X
Post by
whytestocks
on Apr 15, 2024 5:30pm
Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Sto
JUST IN: $MRNS Why Did Epilepsy/Seizure Focused-Marinus Pharmaceuticals Stock Hit 52-Week Low On Monday? | BenzingaMonday,@Marinus Pharmaceuticals Inc@(NASDAQ:MRNS) announced that an independent Data
...more
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 18, 2022 3:04pm
MRNS .... Not giving Mr. M any money back ; )
Happy Fryday !
(72)
•••
Iseneschal
X
Post by
Iseneschal
on Mar 18, 2022 3:01pm
MRNS ....late morning NR and Halt ; )
SCalped it for $2 / share Thank you !
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Learn How this Company is Disrupting Point-of-Care Testing
Unique Battery Metals opportunity in Quebec
Discover Options Trading Strategies to Minimize your Tax Burden
Rig Count Soars as Utilization Surpasses Industry Averages
Debt-Free Cannabis Company Set for Next Stage of Growth